SEC Form 4 · accession 0001325812-18-000002
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Mason
Officer — VP, Finance and Treasurer
Period of report
Dec 30, 2017
Accepted (ET)
Jan 3, 2018 · 5:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 30, 2017 | M | 8,502 | $0.00 | A | 8,502 | D | |
| Common Stock | Dec 30, 2017 | F | 3,538 | $127.05 | D | 4,964 | D | |
| Common StockF1 | holding | — | — | — | 226 | I | by Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF2,F3 | — | Dec 30, 2017 | M | 8,502 | D | — | — | Common Stock | 8,502 | 0 | D |
Explanation of responses
- F1The reporting person owns 226 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F2Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.
- F3The restricted stock units vest in full on December 30, 2017.